Pre-market hot trades in US stocks: Cel-Sci up 7.38% in pre-market, can management's buyback and progress in cancer immunotherapy offset financial weakness?

Popular Pre-Market Trades in US Stocks CEL-SCI is up 7.38% in pre-market trading. Based on recent key news: On May 14, Geert R Kersten, the director and CEO of Cel-Sci, purchased 300,000 shares of the company stock for $360,000. This move demonstrates management's confidence in the company's future development, driving the stock price up. Source: AASTOCKS On May 15, Cel-Sci's financial performance was weak, and technical indicators showed a strong downward trend. Despite signs of being oversold, negative earnings and no dividends limited the valuation. This information put pressure on the stock price. Source: Spark On May 18, Cel-Sci released news via Business Wire, emphasizing its progress in cancer immunotherapy, attracting market attention. Source: Business Wire The biotechnology industry has been volatile recently and requires attention. Top Gainers in Pre-Market US Stocks Sunshine Biopharma is up 551.18% in pre-market trading, with no significant recent news. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. GeoVax Labs is up 165.85% in pre-market trading. Based on recent key news: On May 14, GeoVax Labs announced its strategic focus, emphasizing prioritizing capital and operations on the GEO-MVA project while maintaining Gedeptin development as an important long-term option in combination immunotherapy. This strategic adjustment is considered the main reason for the significant rise in stock price. Data source: SEC announcement. On May 14, GeoVax Labs released original content through the EDGAR system, detailing its strategic adjustments and future development direction. The disclosure of this information increased market confidence in the company's future growth potential, further driving the stock price up. Data source: SEC announcement. On May 14, the market reacted positively to GeoVax Labs' strategic adjustments, with investors expressing optimism about its long-term development potential in combination immunotherapy, leading to a significant pre-market rise in stock price. Data source: SEC announcement. The biotechnology industry has performed strongly recently, with evident capital inflow. FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026) is up 109.36% in pre-market trading, with no significant recent news. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation